Good evening :)
Place Order
Add to Watchlist

IND Swift Laboratories Ltd

INDSWFTLAB

IND Swift Laboratories Ltd

INDSWFTLAB
Health CarePharmaceuticals
SmallcapWith a market cap of ₹616 cr, stock is ranked 1,753
High RiskStock is 3.77x as volatile as Nifty
106.451.99% (+2.08)
106.451.99% (+2.08)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹616 cr, stock is ranked 1,753
High RiskStock is 3.77x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

Low

Undervalued compared to the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹616 cr, stock is ranked 1,753
High RiskStock is 3.77x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
1.650.66—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.726.720.52%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Ind-Swift Laboratories Limited is a company focused on the development of active pharmaceutical ingredients (APIs).

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Revenue Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Earnings Per Share Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 14.34%, vs industry avg of 9.04%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.4% to 0.45%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 70.82%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue667.85737.46784.01876.44813.04914.041,082.231,240.811,712.861,169.08
Raw Materialssubtract352.08377.52374.40421.46409.10457.35581.87673.70628.51619.29
Power & Fuel Costsubtract22.6526.7530.7039.1536.4038.8460.2777.8463.51
Employee Costsubtract66.8569.6588.1297.63102.72106.55127.09135.84152.81
Selling & Administrative Expensessubtract55.3663.1981.2162.1074.8979.1662.8063.6580.66
Operating & Other expensessubtract62.5279.0258.7810.1812.1526.6211.0853.73101.20
Depreciation/Amortizationsubtract84.7588.2686.62104.0590.0687.29131.0457.3653.3026.70
Interest & Other Itemssubtract106.4288.3728.2192.20107.49100.2295.5592.1751.1010.16
Taxes & Other Itemssubtract-24.10-16.1614.0120.731.4221.1614.6838.92160.80139.51
EPS-14.33-9.124.866.21-3.96-0.53-0.368.0371.1463.20
DPS0.000.000.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.000.00
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2015

Annual report

PDF
FY 2016

Annual report

PDF
FY 2017

Annual report

PDF
FY 2018

Annual report

PDF
FY 2019

Annual report

PDF
FY 2020

Annual report

PDF
FY 2021

Annual report

PDF

Investor Presentation

Nov 18PDF
Jul 31PDF
FY 2022

Annual report

PDF
FY 2023

Annual report

PDF
FY 2024

Annual report

PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
IND Swift Laboratories Ltd1.460.66—
Sun Pharmaceutical Industries Ltd46.636.650.73%
Cipla Ltd29.524.540.86%
Mankind Pharma Ltd61.9412.37—

Price Comparison

Compare INDSWFTLAB with any stock or ETF
Compare INDSWFTLAB with any stock or ETF
INDSWFTLAB
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding42.00%0.00%0.94%0.65%56.41%

Mar 2024

Jun 2024

Aug 2024

Sep 2024

Shareholding History

SepDec '23MarJunAugSep0.17%0.31%0.25%1.26%0.85%0.65%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

INDSWFTLAB has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 20, 2011

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Sep 20, 2011

Cash Dividend

Ex DateEx DateSep 16, 2010

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Sep 16, 2010

News & Opinions
Earnings
Ind-Swift Laboratories consolidated net profit declines 98.70% in the September 2024 quarter

Net profit of Ind-Swift Laboratories declined 98.70% to Rs 0.41 crore in the quarter ended September 2024 as against Rs 31.66 crore during the previous quarter ended September 2023. Sales declined 95.87% to Rs 11.96 crore in the quarter ended September 2024 as against Rs 289.71 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales11.96289.71 -96 OPM %-98.6622.67 - PBDT0.8051.95 -98 PBT0.5838.77 -99 NP0.4131.66 -99 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Ind-Swift Laboratories to declare Quarterly Result

Ind-Swift Laboratories will hold a meeting of the Board of Directors of the Company on 11 November 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Ind-Swift Laboratories to hold AGM

Ind-Swift Laboratories announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Ind-Swift Laboratories consolidated net profit declines 94.55% in the June 2024 quarter

Net profit of Ind-Swift Laboratories declined 94.55% to Rs 0.94 crore in the quarter ended June 2024 as against Rs 17.24 crore during the previous quarter ended June 2023. Sales declined 89.31% to Rs 33.17 crore in the quarter ended June 2024 as against Rs 310.34 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales33.17310.34 -89 OPM %-29.3619.43 - PBDT1.2345.52 -97 PBT0.9831.64 -97 NP0.9417.24 -95 Powered by Capital Market - Live

4 months agoCapital Market - Live
Earnings
Ind-Swift Laboratories standalone net profit declines 63.70% in the June 2024 quarter

Net profit of Ind-Swift Laboratories declined 63.70% to Rs 6.19 crore in the quarter ended June 2024 as against Rs 17.05 crore during the previous quarter ended June 2023. Sales declined 89.81% to Rs 30.46 crore in the quarter ended June 2024 as against Rs 299.01 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales30.46299.01 -90 OPM %-14.8720.01 - PBDT6.4444.99 -86 PBT6.1931.10 -80 NP6.1917.05 -64 Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Ind-Swift Laboratories to discuss results

Ind-Swift Laboratories will hold a meeting of the Board of Directors of the Company on 12 August 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live

Why shares of PI Industries are down 8% today? Good time to buy?

3 years agoLivemint

PI Industries decline after terminating business transfer agreement with Ind Swift

3 years agoBusiness Standard

PI Industries: A Sizeable Entry Into Pharma

3 years agoMoneycontrol

PI Industries to acquire Ind Swift’s API biz for Rs 1,530 cr

3 years agoFree Press Journal